C
33.39
1.02 (3.15%)
| Previous Close | 32.37 |
| Open | 32.30 |
| Volume | 931,405 |
| Avg. Volume (3M) | 1,009,032 |
| Market Cap | 3,106,889,216 |
| Price / Sales | 2.34 |
| Price / Book | 2.12 |
| 52 Weeks Range | |
| Earnings Date | 8 May 2025 |
| Operating Margin (TTM) | -32,613.47% |
| Diluted EPS (TTM) | -3.69 |
| Quarterly Revenue Growth (YOY) | -59.60% |
| Total Debt/Equity (MRQ) | 3.90% |
| Current Ratio (MRQ) | 23.05 |
| Operating Cash Flow (TTM) | -225.97 M |
| Levered Free Cash Flow (TTM) | -136.41 M |
| Return on Assets (TTM) | -20.46% |
| Return on Equity (TTM) | -32.02% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Crinetics Pharmaceuticals, Inc. | Bearish | Bullish |
AIStockmoo Score
2.8
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 4.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 2.0 |
| Average | 2.75 |
|
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 2.14% |
| % Held by Institutions | 110.91% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 91.00 (Citizens Capital Markets, 172.54%) | Buy |
| Median | 75.50 (126.12%) | |
| Low | 60.00 (Stifel, 79.70%) | Buy |
| Average | 75.50 (126.12%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 35.43 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stifel | 25 Mar 2025 | 60.00 (79.69%) | Buy | 35.07 |
| Citizens Capital Markets | 28 Feb 2025 | 91.00 (172.54%) | Buy | 35.78 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |